Bisha Ding

2.1k total citations
34 papers, 1.6k citations indexed

About

Bisha Ding is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bisha Ding has authored 34 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 25 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bisha Ding's work include MicroRNA in disease regulation (20 papers), Cancer-related molecular mechanisms research (17 papers) and Circular RNAs in diseases (13 papers). Bisha Ding is often cited by papers focused on MicroRNA in disease regulation (20 papers), Cancer-related molecular mechanisms research (17 papers) and Circular RNAs in diseases (13 papers). Bisha Ding collaborates with scholars based in China, United States and Singapore. Bisha Ding's co-authors include Weiyang Lou, Weimin Fan, Liang Xu, Weimin Fan, Weiyang Lou, Peifen Fu, Jin‐Xing Liu, Guansheng Zhong, Danni Chen and Chang Bao and has published in prestigious journals such as Frontiers in Immunology, Acta Biomaterialia and Cell Death and Disease.

In The Last Decade

Bisha Ding

34 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bisha Ding China 24 1.2k 1.1k 207 125 84 34 1.6k
Nami Yamada Japan 27 1.5k 1.3× 1.3k 1.2× 138 0.7× 160 1.3× 19 0.2× 47 1.9k
Wenting Pan China 21 840 0.7× 634 0.6× 116 0.6× 163 1.3× 41 0.5× 65 1.2k
Hui-Wen Cheng Taiwan 18 523 0.4× 290 0.3× 87 0.4× 192 1.5× 49 0.6× 27 929
Li Zhuang China 16 804 0.7× 644 0.6× 244 1.2× 90 0.7× 7 0.1× 36 1.1k
Danhui Weng China 22 926 0.8× 471 0.4× 79 0.4× 492 3.9× 28 0.3× 41 1.5k
Yu Dong China 19 549 0.4× 380 0.4× 128 0.6× 149 1.2× 20 0.2× 61 1.0k
Fei‐Ran Gong China 22 486 0.4× 375 0.4× 145 0.7× 422 3.4× 17 0.2× 38 1.1k
Jingjing Zhang China 21 893 0.7× 565 0.5× 107 0.5× 384 3.1× 20 0.2× 62 1.4k
Xuefeng Xia China 14 363 0.3× 257 0.2× 118 0.6× 192 1.5× 33 0.4× 33 777

Countries citing papers authored by Bisha Ding

Since Specialization
Citations

This map shows the geographic impact of Bisha Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bisha Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bisha Ding more than expected).

Fields of papers citing papers by Bisha Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bisha Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bisha Ding. The network helps show where Bisha Ding may publish in the future.

Co-authorship network of co-authors of Bisha Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Bisha Ding. A scholar is included among the top collaborators of Bisha Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bisha Ding. Bisha Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Zhou, Wei, Weiyang Lou, Junru Chen, et al.. (2021). AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest. OncoTargets and Therapy. Volume 14. 1049–1059. 3 indexed citations
4.
Lou, Weiyang, Jing Chen, Bisha Ding, & Weimin Fan. (2021). XIAP, commonly targeted by tumor suppressive miR-3607-5p and miR-3607-3p, promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Genomics. 113(3). 933–945. 11 indexed citations
5.
Zheng, Huilin, et al.. (2021). Construction of a lncRNA/pseudogene-hsa-miR-30d-5p-GJA1 regulatory network related to metastasis of pancreatic cancer. Genomics. 113(4). 1742–1753. 15 indexed citations
6.
Lou, Weiyang, Bisha Ding, & Peifen Fu. (2020). Pseudogene-Derived lncRNAs and Their miRNA Sponging Mechanism in Human Cancer. Frontiers in Cell and Developmental Biology. 8. 85–85. 114 indexed citations
7.
Ding, Bisha, Weimin Fan, & Weiyang Lou. (2020). hsa_circ_0001955 Enhances In Vitro Proliferation, Migration, and Invasion of HCC Cells through miR-145-5p/NRAS Axis. Molecular Therapy — Nucleic Acids. 22. 445–455. 64 indexed citations
8.
Lou, Weiyang, Bisha Ding, Guansheng Zhong, et al.. (2020). RP11-480I12.5-004 Promotes Growth and Tumorigenesis of Breast Cancer by Relieving miR-29c-3p-Mediated AKT3 and CDK6 Degradation. Molecular Therapy — Nucleic Acids. 21. 916–931. 23 indexed citations
9.
Gao, Shan, Bisha Ding, & Weiyang Lou. (2020). microRNA-Dependent Modulation of Genes Contributes to ESR1's Effect on ERα Positive Breast Cancer. Frontiers in Oncology. 10. 753–753. 26 indexed citations
10.
Lou, Weiyang, et al.. (2020). The Involvement of the hsa_circ_0088494-miR-876-3p-CTNNB1/CCND1 Axis in Carcinogenesis and Progression of Papillary Thyroid Carcinoma. Frontiers in Cell and Developmental Biology. 8. 605940–605940. 40 indexed citations
11.
Bao, Chang, Danni Chen, Yunkun Lu, et al.. (2020). MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1. Cell Death and Disease. 11(8). 618–618. 44 indexed citations
12.
Chen, Xu, Weiyang Lou, Jin‐Xing Liu, et al.. (2019). A novel antimicrobial polymer efficiently treats multidrug-resistant MRSA-induced bloodstream infection. Bioscience Reports. 39(10). 14 indexed citations
13.
Lou, Weiyang, Bisha Ding, & Weimin Fan. (2019). High Expression of Pseudogene PTTG3P Indicates a Poor Prognosis in Human Breast Cancer. Molecular Therapy — Oncolytics. 14. 15–26. 46 indexed citations
14.
Bao, Chang, Yunkun Lu, Danni Chen, et al.. (2019). Exploring specific prognostic biomarkers in triple-negative breast cancer. Cell Death and Disease. 10(11). 807–807. 61 indexed citations
15.
Lou, Weiyang, Jin‐Xing Liu, Bisha Ding, et al.. (2019). Identification of potential miRNA–mRNA regulatory network contributing to pathogenesis of HBV-related HCC. Journal of Translational Medicine. 17(1). 7–7. 77 indexed citations
16.
Yang, Shaolong, et al.. (2019). Distinct expression pattern and prognostic values of pituitary tumor transforming gene family genes in non‑small cell lung cancer. Oncology Letters. 18(5). 4481–4494. 10 indexed citations
17.
Yang, Chuan, Weiyang Lou, Guansheng Zhong, et al.. (2019). Degradable antimicrobial polycarbonates with unexpected activity and selectivity for treating multidrug-resistant Klebsiella pneumoniae lung infection in mice. Acta Biomaterialia. 94. 268–280. 45 indexed citations
18.
Lou, Weiyang, Jing Chen, Bisha Ding, et al.. (2018). Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation. Journal of Translational Medicine. 16(1). 266–266. 70 indexed citations
19.
Lou, Weiyang, Jin‐Xing Liu, Bisha Ding, Liang Xu, & Weimin Fan. (2018). Identification of chemoresistance-associated miRNAs in breast cancer. Cancer Management and Research. Volume 10. 4747–4757. 51 indexed citations
20.
Lou, Weiyang, S. Venkataraman, Guansheng Zhong, et al.. (2018). Antimicrobial polymers as therapeutics for treatment of multidrug-resistant Klebsiella pneumoniae lung infection. Acta Biomaterialia. 78. 78–88. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nami Yamada Breakdown of academic impact, for papers by Wenting Pan Breakdown of academic impact, for papers by Hui-Wen Cheng Breakdown of academic impact, for papers by Li Zhuang Breakdown of academic impact, for papers by Danhui Weng Breakdown of academic impact, for papers by Yu Dong Breakdown of academic impact, for papers by Fei‐Ran Gong Breakdown of academic impact, for papers by Jingjing Zhang Breakdown of academic impact, for papers by Xuefeng Xia
Rankless by CCL
2026